Cognitive and Behavioral Profiles of Children with Aspartylglucosaminuria: A Case Series

Abstract

Aspartylglucosaminuria (AGU) is a rare lysosomal storage disorder with an autosomal recessive inheritance. It affects the aspartylglucosaminidase (AGA) gene and causes a deficiency in activity of the enzyme N-aspartyl-β-glucosaminidase with resultant accumulation of glycoasparagines in body tissues. Children with AGU present with developmental delays in cognitive and language skills. Currently, information on cognition and behavior of children with AGU is limited. This case series presents the neuropsychological and behavioral profiles of three children with AGU assessed at two time points. All the three children had full-scale intelligence quotient (IQ) scores in the intellectual disabled range (<70). IQ had declined since their previous cognitive assessment 1 to 2 years prior. Other cognitive skills were significantly below expected levels. Parents reported several behavioral problems and adaptive difficulties. The findings challenge current beliefs that cognition is impaired but stable in children with declines seen in a short time.

Keywords

aspartylglucosaminuria - lysosomal storage disorder - cognition - children - behavior

Publication History

Received: 08 February 2021

Accepted: 25 March 2021

Article published online:
19 June 2021

• References

• 1 Arvio M, Mononen I. Aspartylglycosaminuria: a review. Orphanet J Rare Dis 2016; 11 (01) 162
• 2 Mononen T, Mononen I, Matilainen R, Airaksinen E. High prevalence of aspartylglycosaminuria among school-age children in eastern Finland. Hum Genet 1991; 87 (03) 266-268
• 3 Autio S. Aspartylglycosaminuria. Analysis of thirty-four patients. J Ment Defic Res 1972; 1 (00) 1-93
• 4 Arvio P, Arvio M. Progressive nature of aspartylglucosaminuria. Acta Paediatr 2002; 91 (03) 255-257
• 5 Arvio M, Sauna-Aho O, Peippo M. Bone marrow transplantation for aspartylglucosaminuria: follow-up study of transplanted and non-transplanted patients. J Pediatr 2001; 138 (02) 288-290
• 6 Banning A, Gülec C, Rouvinen J, Gray SJ, Tikkanen R. Identification of small molecule compounds for pharmacological chaperone therapy of aspartylglucosaminuria. Sci Rep 2016; 6: 37583
• 7 Arvio M. Follow-up in patients with aspartylglucosaminuria. Part I. The course of intellectual functions. Acta Paediatr 1993; 82 (05) 469-471
• 8 Malm G, Månsson J-E, Winiarski J, Mosskin M, Ringdén O. Five-year follow-up of two siblings with aspartylglucosaminuria undergoing allogeneic stem-cell transplantation from unrelated donors. Transplantation 2004; 78 (03) 415-419
• 9 Harjunen EL, Laine M, Tikkanen R, Helenius P. Detailed profile of cognitive dysfunction in children with aspartylglucosaminuria. J Inherit Metab Dis 2020; 43 (02) 318-325
• 10 Arvio M. Follow-up in patients with aspartylglucosaminuria. Part II. Adaptive skills. Acta Paediatr 1993; 82 (6-7): 590-594
• 11 Wechsler D. Wechsler Preschool and Primary Scale of Intelligence. 3rd ed.. Australian Standardised Edition. Sydney, Australia: Pearson PsychCorp; 2002
• 12 Wechsler D. Wechsler Preschool and Primary Scale of Intelligence. 4th ed.. San Antonio, TX: Psychological Corporation; 2012
• 13 Wechsler D. Wechsler Intelligence Scale for Children, Fourth Edition. Sydney, Australia: Psychological Corporation; 2003
• 14 Korkman M, Kirk U, Kemp S. NEPSY, Second Edition (NEPSY-II), Administration Manual. San Antonio, TX: Pearson; 2007
• 15 Reynolds CR, Kamphaus RW. Behavior Assessment System for Children, Second Edition. Bloomington, MN: Pearson; 2004
• 16 Harrison P, Oakland T. Adaptive Behavior Assessment System, Second Edition. San Antonio, TX: Western Psychological Services; 2003
• 17 Campistol J, Díez-Juan M, Callejón L. et al. Inborn error metabolic screening in individuals with nonsyndromic autism spectrum disorders. Dev Med Child Neurol 2016; 58 (08) 842-847